Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis

Gene Therapy

Volumn 24, Issue 11, 2017, Pages 706-716

  Tomaru, A ^a   Kobayashi, T ^a   Hinneh, J A ^a   Tonto, P Baffour ^a   D'Alessandro Gabazza, C N ^a   Fujimoto, H ^a   Fujiwara, K ^a   Takahashi, Y ^a   Ohnishi, M ^a   Yasuma, T ^a   Nishihama, K ^a   Yoshino, M ^c   Takao, K ^c   Toda, M ^a   Totoki, T ^c   Takei, Y ^a   Yoshikawa, K ^c   Taguchi, O ^b   Gabazza, E C ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY   (Japan)

^c AQUA Therapeutics Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTISENSE OLIGONUCLEOTIDE; COLLAGEN TYPE 1; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; BLEOMYCIN; CELL ADHESION MOLECULE; COLLAGEN; OLIGONUCLEOTIDE; POSTN PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEUKOCYTE DIFFERENTIAL COUNT; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS WALL; LUNG FIBROSIS; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PLEURA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ANIMAL; C57BL MOUSE; FIBROBLAST; FIBROSING ALVEOLITIS; FIBROSIS; GENETICS; INTRANASAL DRUG ADMINISTRATION; LUNG; METABOLISM; PHYSIOLOGY; PROCEDURES;

ADMINISTRATION, INTRANASAL; ANIMALS; BLEOMYCIN; CELL ADHESION MOLECULES; COLLAGEN; FEMALE; FIBROBLASTS; FIBROSIS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PULMONARY FIBROSIS; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA;

EID: 85036652987     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2017.80     Document Type: Article

References (40)

1. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-529.
2. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-525.
3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
4. George G, Vaid U, Summer R. Therapeutic advances in idiopathic pulmonary fibrosis. Clin Pharmacol Ther 2016; 99: 30-32.
5. Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012; 5: 11.
6. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 1999; 14: 1239-1249.
7. Izuhara K, Conway SJ, Moore BB, Matsumoto H, Holweg CT, Matthews JG et al. Roles of periostin in respiratory disorders. Am J Respir Crit Care Med 2016; 193: 949-956.
8. Conway SJ, Doetschman T, Azhar M. The inter-relationship of periostin, TGF beta, and BMP in heart valve development and valvular heart diseases. Scientific World Journal 2011; 11: 1509-1524.
9. Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303: L1046-L1056.
10. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L et al. Roles of epithelial cellderived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010; 107: 14170-14175.
11. Uchida M, Shiraishi H, Ohta S, Arima K, Taniguchi K, Suzuki S et al. Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 46: 677-686.
12. Chery J, Naar A. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J 2016; 4: 35-50.
13. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655.
14. Novina CD, Sharp PA. The RNAi revolution. Nature 2004; 430: 161-164.
15. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 2015; 87: 46-51.
16. Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 2013; 76: 269-276.
17. Moreno PM, Pego AP. Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem 2014; 2: 87.
18. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 2015; 87: 108-119.
19. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988; 41: 467-470.
20. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014; 9: 157-179.
21. Tajiri M, Okamoto M, Fujimoto K, Johkoh T, Ono J, Tominaga M et al. Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Respir Investig 2015; 53: 73-81.
22. D'Alessandro-Gabazza CN, Kobayashi T, Boveda-Ruiz D, Takagi T, Toda M, Gil-Bernabe P et al. Development and preclinical efficacy of novel transforming growth factor-beta1 short interfering RNAs for pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 46: 397-406.
23. Ohta S, Okamoto M, Fujimoto K, Sakamoto N, Takahashi K, Yamamoto H et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS ONE 2017; 12: e0174547.
24. Moschos SA, Spinks K, Williams AE, Lindsay MA. Targeting the lung using siRNA and antisense based oligonucleotides. Curr Pharm Des 2008; 14: 3620-3627.
25. Snove O Jr., Holen T. Many commonly used siRNAs risk off-target activity. Biochem Biophys Res Commun 2004; 319: 256-263.
26. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006; 13: 644-670.
27. Nyce JW, Metzger WJ. DNA antisense therapy for asthma in an animal model. Nature 1997; 385: 721-725.
28. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-55.
29. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001; 193: 1247-1260.
30. Torres R, Herrerias A, Serra-Pages M, Roca-Ferrer J, Pujols L, Marco A et al. An intranasal selective antisense oligonucleotide impairs lung cyclooxygenase-2 production and improves inflammation, but worsens airway function, in house dust mite sensitive mice. Respir Res 2008; 9: 72.
31. Miller MA, Stabenow JM, Parvathareddy J, Wodowski AJ, Fabrizio TP, Bina XR et al. Visualization of murine intranasal dosing efficiency using luminescent Francisella tularensis: effect of instillation volume and form of anesthesia. PLoS One 2012; 7: e31359.
32. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210.
33. Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 2015; 24: 102-114.
34. Luzina IG, Todd NW, Iacono AT, Atamas SP. Roles of T lymphocytes in pulmonary fibrosis. J Leukoc Biol 2008; 83: 237-244.
35. Stahl M, Schupp J, Jager B, Schmid M, Zissel G, Muller-Quernheim J et al. Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. PLoS ONE 2013; 8: e81382.
36. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L152-L160.
37. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-827.
38. Crawford J, Nygard K, Gan BS, O'Gorman DB. Periostin induces fibroblast proliferation and myofibroblast persistence in hypertrophic scarring. Exp Dermatol 2015; 24: 120-126.
39. Yang L, Serada S, Fujimoto M, Terao M, Kotobuki Y, Kitaba S et al. Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma. PLoS ONE 2012; 7: e41994.
40. Urawa M, Kobayashi T, D'Alessandro-Gabazza CN, Fujimoto H, Toda M, Roeen Z et al. Protein S is protective in pulmonary fibrosis. J Thromb Haemost 2016; 14: 1588-1599.